

Resource Summary Report

Generated by [RRID](#) on Jul 31, 2026

Anti-Bim Antibody, Unconjugated

RRID:AB_10692515

Type: Antibody

Proper Citation

Cell Signaling Technology Cat# 2819, RRID:AB_10692515

Antibody Information

URL: http://antibodyregistry.org/AB_10692515

Proper Citation: Cell Signaling Technology Cat# 2819, RRID:AB_10692515

Target Antigen: Bim

Clonality: unknown

Comments: Applications: W, IP. Consolidation on 10/2018: AB_10692515, AB_659953.

Antibody Name: Anti-Bim Antibody, Unconjugated

Description: This unknown targets Bim

Target Organism: monkey, simian, mouse, human

Antibody ID: AB_10692515

Vendor: Cell Signaling Technology

Catalog Number: 2819

Record Creation Time: 20250820T014811+0000

Record Last Update: 20250820T115348+0000

Ratings and Alerts

No rating or validation information has been found for Anti-Bim Antibody, Unconjugated.

No alerts have been found for Anti-Bim Antibody, Unconjugated.

Data and Source Information

Usage and Citation Metrics

We found 18 mentions in open access literature.

Listed below are recent publications. The full list is available at [RRID](#) .

Matkar S, et al. (2025) Kinome Reprogramming of G2/M Kinases and Repression of MYCN Contribute to Superior Efficacy of Lorlatinib in ALK-Driven Neuroblastoma. *Molecular cancer therapeutics*, 24(9), 1389.

Baro M, et al. (2025) Redundancy of the OST catalytic subunit facilitates therapeutic targeting of N-glycosylation. *Cell chemical biology*, 32(6), 839.

Van Der Byl W, et al. (2024) The CD8+ T cell tolerance checkpoint triggers a distinct differentiation state defined by protein translation defects. *Immunity*, 57(6), 1324.

Pieper NM, et al. (2024) Inhibition of bromodomain and extra-terminal proteins targets constitutively active NF κ B and STAT signaling in lymphoma and influences the expression of the antiapoptotic proteins BCL2A1 and c-MYC. *Cell communication and signaling : CCS*, 22(1), 415.

Perurena N, et al. (2023) USP9X mediates an acute adaptive response to MAPK suppression in pancreatic cancer but creates multiple actionable therapeutic vulnerabilities. *Cell reports. Medicine*, 4(4), 101007.

Mertens S, et al. (2023) Drug-repurposing screen on patient-derived organoids identifies therapy-induced vulnerability in KRAS-mutant colon cancer. *Cell reports*, 42(4), 112324.

Liu Y, et al. (2023) Artesunate, a new antimalarial clinical drug, exhibits potent anti-AML activity by targeting the ROS/Bim and TFRC/Fe²⁺ pathways. *British journal of pharmacology*, 180(6), 701.

Pan R, et al. (2022) Augmenting NK cell-based immunotherapy by targeting mitochondrial apoptosis. *Cell*, 185(9), 1521.

Cai J, et al. (2022) High-risk neuroblastoma with NF1 loss of function is targetable using SHP2 inhibition. *Cell reports*, 40(4), 111095.

Pearson JM, et al. (2020) Ceramide Analogue SACLAC Modulates Sphingolipid Levels and MCL-1 Splicing to Induce Apoptosis in Acute Myeloid Leukemia. *Molecular cancer research : MCR*, 18(3), 352.

Loo LSW, et al. (2020) BCL-xL/BCL2L1 is a critical anti-apoptotic protein that promotes the survival of differentiating pancreatic cells from human pluripotent stem cells. *Cell death & disease*, 11(5), 378.

Zierhut C, et al. (2019) The Cytoplasmic DNA Sensor cGAS Promotes Mitotic Cell Death. *Cell*, 178(2), 302.

Burmi RS, et al. (2019) Combined inhibition of the PI3K/mTOR/MEK pathway induces Bim/Mcl-1-regulated apoptosis in pancreatic cancer cells. *Cancer biology & therapy*, 20(1), 21.

Michael IP, et al. (2019) ALK7 Signaling Manifests a Homeostatic Tissue Barrier That Is Abrogated during Tumorigenesis and Metastasis. *Developmental cell*, 49(3), 409.

Guièze R, et al. (2019) Mitochondrial Reprogramming Underlies Resistance to BCL-2 Inhibition in Lymphoid Malignancies. *Cancer cell*, 36(4), 369.

Wang L, et al. (2018) Mitofusin 2 Regulates Axonal Transport of Calpastatin to Prevent Neuromuscular Synaptic Elimination in Skeletal Muscles. *Cell metabolism*, 28(3), 400.

Pan R, et al. (2017) Synthetic Lethality of Combined Bcl-2 Inhibition and p53 Activation in AML: Mechanisms and Superior Antileukemic Efficacy. *Cancer cell*, 32(6), 748.

Cao B, et al. (2016) Inactivation of oncogenic cAMP-specific phosphodiesterase 4D by miR-139-5p in response to p53 activation. *eLife*, 5.